Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal, +8

Annals of Oncology

First-line TherapyOncologyOverall SurvivalMetronomic TherapyClinical Trials +6

Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS

Mark Vincent, M. Sara Kuruvilla, N. B. Leighl, +1

Current Oncology

Clinical EndpointPathologyTumor BiologyKras Mutational StatusBiomarker (Medicine) +17

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

Heather A. Wakelee, Suzanne E. Dahlberg, S.M. Keller, +5

Journal of Clinical Oncology

Preclinical TherapeuticsSurgical OncologyEarly Stage NsclcPathologyMetronomic Chemotherapy +18

A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

V. Papadimitrakopoulou, G. R. Blumenschein, N. B. Leighl, +7

Journal of Clinical Oncology

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

N. B. Leighl, Catherine A. Shu, Anna Minchom, +17

Annals of Oncology

Amivantamab MonotherapyPost-osimertinib Egfr-mutant NsclcMedicineChrysalis StudyPharmacology +6

An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer

Anne M. Horgan, Penelope A. Bradbury, Eitan Amir, +5

Annals of Oncology

MedicineInterest TrialClinical TrialsEconomic AnalysisPharmacotherapy +7

Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

Christos S. Karapetis, P. Clingan, N. B. Leighl, +3

Journal of Clinical Oncology

ImmunologyPathologyCell DeathPhase Ii StudyAmino Acid 131 +16

A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

Peter Ellis, Quincy S. Chu, N. B. Leighl, +5

Journal of Clinical Oncology

Escalation TrialBi 2536MedicinePharmacologyImmune Checkpoint Inhibitor +10

PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

Isabelle Côté, N. B. Leighl, Marlene Gyldmark, +1

Value in Health

MedicineCancer ManagementPharmacologyPharmacotherapyCancer Treatment +2

Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL)

N. B. Leighl, Petr Zatloukal, J. Mezger, +4

Journal of Clinical Oncology

Elderly PatientsCancer ManagementPharmacotherapyLogistic AnalysisPhase Iii Trial +15